Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 5,92 € (-74,13 %). Medianen er 5,92 € (-74,13 %).
| Køb |
3 |
| Behold |
5 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Treace Medical beats Q2 forecasts; shares jump about 24% premarket
Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Mere på de.investing.com
Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly
Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Mere på de.investing.com
Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand
Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Mere på de.investing.com
Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making
Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Mere på de.investing.com
Treace Medical Concepts beats Q2 forecasts and shares rise after hours
Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 42,6 mio. | 0,44 % |
| Bruttofortjeneste | 33,86 mio. | 0,07 % |
| Nettoresultat | -11,09 mio. | 20,07 % |
| EBITDA | -9,7 mio. | 6,52 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 264,93 mio. € |
Antal aktier | 65,56 mio. |
Højeste/laveste i 52 uger | 4,95 € - 1,06 € |
| Udbytte | Nej |
Beta | 1,56 |
P/E (PE Ratio) | -5,16 |
PEG (PEG Ratio) | 0,49 |
K/I (PB Ratio) | 4,72 |
P/S (PS Ratio) | 1,43 |
Virksomhedsprofil
Treace Medical Concepts, Inc. er en ortopædisk medicinsk udstyrsvirksomhed, der designer, fremstiller og markedsfører medicinsk udstyr til fod- og ankelkirurger i USA. Virksomheden tilbyder Lapiplasty-proceduren, som gør det muligt for podiatriske kirurger at behandle alle tre dimensioner af hallux valgus (vabler), hvilket giver patienterne en kosmetisk og medicinsk forbedring. Virksomheden leverer også Lapiplasty Mini-Incision precisionssystemet. Derudover tilbyder den produkter til at håndtere supplerende kirurgiske procedurer, herunder akin-osteotomier, weil-osteotomier, intercuneiform-stabilisering, fusioner af den laterale tarsometatarsale led samt høst af autograft-knogle, og også til MTP-fusion. Treace Medical Concepts, Inc. blev grundlagt i 2013 og har hovedkontor i Ponte Vedra Beach, Florida.
| Navn | Treace Medical Concepts |
| CEO | John T. Treace |
| Hjemsted | Ponte Vedra,
fl USA |
| Websted | |
| Sektor | Cykliske forbrugsvarer |
| Branche | Forbrugsgoder |
| Børsnotering | 23.04.2021 |
| Medarbejdere | 450 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | TMCI |